The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1294
Monthly Risedronate (Actonel) for Postmenopausal Osteoporosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The bisphosphonate risedronate (Actonel – Procter & Gamble) was recently approved by the FDA in a 150-mg once-monthly oral tablet for prevention and treatment of postmenopausal osteoporosis. The drug is also available for the same indication in 5-mg daily, 35-mg weekly and 75-mg twice-monthly tablets.

BISPHOSPHONATES FOR OSTEOPOROSIS — Risedronate, alendronate (Fosamax, and others) and ibandronate (Boniva) are bisphosphonates approved for oral treatment and/or prevention of osteoporosis. Ibandronate is the only other bisphosphonate available in a tablet given once monthly.1 Oral bisphosphonates can cause heartburn, esophageal irritation and esophagitis. To ensure adequate absorption (at best <1% is absorbed) and avoid esophageal injury, they require a regimen that some patients find difficult. The drug must be taken with 8 ounces of plain water after an overnight ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Monthly Risedronate (Actonel) for Postmenopausal Osteoporosis
Article code: 1294a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian